An observational study in Obesity and Diabetes Mellitus, Type 2, sponsored by Cleveland Clinic London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Cleveland Clinic London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Obesity with a site in United Kingdom — 94 open to participants now, 128 under way, 41 of them phase 3. Obesity · United Kingdom.
Among the 454 studies in Obesity with a site in United Kingdom, this one is the 31st largest by planned enrollment of the 81 observational ones that give a count, is one of 20 that started in 2024, is one of 81 observational ones, reaches primary completion later than 127 of the 127 other live ones, and was the 353rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →94 of the 454 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United Kingdom, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in United Kingdom, United States, Germany and 1 more country
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Taiwan
Ages 40+
Elenzia · Sites in United Kingdom
Ages 25–65
StudySetGo · Sites in United Kingdom
Ages 30–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 36 · Phase 3 77 · Phase 4 12
First in 2001; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 66 across the 372 interventional studies, 130 across the 81 observational. Of the 272 that completed or were terminated, 53 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 454 have an industry lead sponsor. The 10 most frequent:
Cleveland Clinic London is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Cleveland Clinic London has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
29 of the studies in Obesity with a site in United Kingdom that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 454 studies in Obesity with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.
This is a national, multi-centre, prospective, UK registry that aims to determine the safety and efficacy of metabolic and bariatric endoscopic procedures used in the treatment of obesity and related complications. The investigators will do this by determining the effect of primary bariatric procedures (gastroplasty, intragastric balloons (IGB)), revisional bariatric procedures (Transoral outlet reduction endoscopy (TORe), gastroplasty revision), and primary metabolic procedures (Duodenal Mucosal Resurfacing (DMR)), completed by endoscopists within the UK.
The objective of this registry is to collect demographic, procedural and follow-up outcome data on the use of metabolic and bariatric endoscopic procedures in patients with obesity and/or obesity-related complications. This registry will provide real-life outcomes on the use of these novel endoscopic devices from multiple centres participating across the UK to provide longer-term safety and efficacy data. In addition, the registry will enable development of a UK-wide research network to support further research, innovation, and training into metabolic and bariatric endoscopy.
Adult patients within the United Kingdom (UK) who have, or plan to, undergo a primary or revisional bariatric or metabolic endoscopic procedure for the treatment of obesity or metabolic disease in the UK
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Endoscopic gastric suturing · Device: Endoscopic gastric plication · Device: Intragastric balloon(s)
Device: Revisional gastroplasty · Device: Transoral outlet reduction endoscopy (TORe)
Device: Duodenal mucosal resurfacing (DMR)
Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
Also known as: Endoscopic sleeve gastroplasty (ESG; Apollo Overstitch)
Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
Also known as: Primary obesity surgery endoluminal (POSE), Endomina system
Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
Total body weight loss percentage (TBWL%)
For primary or revisional bariatric procedures: Percentage weight loss will be calculated using the following formula: TBWL% = \[(weight at the baseline-weight at the end of time period)/weight at baseline\] x 100
Time frame: 6-months, 1-, 2-, 3-, 5-years
Change in glycated haemoglobin (HbA1c; mmol/mol)
For primary metabolic procedures
Time frame: 6-months, 1-, 2-, 3-, 5-years
Change in the number and dose of anti-diabetic medications
For primary metabolic procedures
Time frame: 6-months, 1-, 2-, 3-, 5-years
Procedure time (mins)
Time frame: Baseline
Inpatient stay (days)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Adverse events
Time frame: 30-day, 6-months, 1-, 2-, 3-, 5-years
Change in systolic blood pressure measurements (mmHg)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Change in diastolic blood pressure measurements (mmHg)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in number and dose of anti-hypertensive medications (n)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in low-density lipoprotein cholesterol (mmol/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in triglycerides (mmol/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in high-density lipoprotein cholesterol (mmol/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in total cholesterol (mmol/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in alanine transaminase (IU/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in aspartate aminotransferase (IU/L)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in Fibrosis-4 Index for Liver Fibrosis
The Fibrosis-4 Index for Liver Fibrosis provides a probability score for the presence of hepatic fibrosis. It is based on age, ALT, AST, and platelet count. The range of the score is wide but there are two main cut-offs point for prediction of advanced fibrosis (\<1.3 and \>2.67). Higher scores indicate a higher likelihood of advanced fibrosis.
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in non-alcoholic fatty liver disease fibrosis score
The non-alcoholic fatty liver disease fibrosis score provides a probability score for the presence of hepatic fibrosis. It is based on age, body mass index, impaired fasting glucose, ALT, AST, albumin and platelet count. The range of the score is wide but there are two main cut-offs for prediction of advanced fibrosis (\<-1.455 and \>0.676). Higher scores indicate a higher likelihood of advanced fibrosis.
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in weight (kg)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in body mass index (kg/m2)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in glycated haemoglobin (HbA1c; mmol/mol)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in number and dose of anti-diabetic medications (n)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in number and dose of anti-obesity medications (n)
Time frame: 6-months, 1-, 2-, 3-, 5-years
Changes in health-related quality of life scores (EuroQol-5D-5L)
The EuroQol-5D-5L is a quality of life questionnaire that is composed of five questions scored 1-5 that do not have an arithmetic value and a visual analogue scale between 0-100. Participants are simply given a five digit code (e.g. 13455) and a visual analogue score (e.g. 78), which can then be interpreted through reference value sets in the corresponding country.
Time frame: 6-months, 1-, 2-, 3-, 5-years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2034, 120 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 120 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cleveland Clinic London